



# PantoCIN newsletter

Issue 6, March 2020

## COVID-19



### Support and guidance during COVID-19 pandemic

We wish to do our best to support PantoCIN sites during this unusual time for us all, if you have a participant receiving study treatment and their visits and/or assessments are set to alter due to the restrictions relating to COVID-19, then please contact us to discuss any issues you may have, whether these are expected or have already occurred. Safety of participants and maintaining the integrity of study data remain vital to the study.

Guidance and anticipated changes for sites undertaking recruitment and follow up during this time are available in the document: **CTNZ support and advice for sites re COVID-19.**

### Participants

Participants currently receiving study treatment or those who have completed their study treatment, may have questions or concerns about the study. Any queries or discussions, discussed at site, can also be raised with the PantoCIN Trial Management Committee, please contact us.

### Primary endpoint data

Participant primary endpoint data for PantoCIN is vital data that patients submit using questionnaires. Participants are given the option of using an app/website or completing paper questionnaires. If there is any problem with completing questionnaires, then the participant may complete them on the telephone with a member of the delivery team. If the participant is not able to attend hospital, then please consider providing the stamped addressed envelopes, in your site file, with your hospital address, for return.

### Study monitoring

We will continue to review the monitoring plan for the study and will support changes which allow flexibility and are pragmatic for the COVID-19 situation. Details of changes will be sent to sites, as required.

### Contact us

Many of the CTNZ team are working remotely, therefore, the best way to contact us is by email or mobile.

*Co-lead PIs*

Richard Isaacs: Richard.Isaacs@midcentraldhb.govt.nz or call 021 243 5210

Navin Wewala: Navin.Wewala@midcentraldhb.govt.nz or call 022 493 9252

*Clinical Trial Manager:* Lou Clement 027 254 3622 or email louise.clement@auckland.ac.nz

**I will hold an open site teleconferences for any staff who wish to dial in and discuss any aspect of the study and also share tips with other PantoCIN sites. Given this busy time you are not obliged to attend, only if it is helpful. Our first one will take place on Friday 27 March at Midday**  
To join us, via Zoom, follow this link:

<https://auckland.zoom.us/j/122933258>

**Other ways to join the call will be circulated separately to this message. Please let me know if you would like to attend.**

### Investigator Site

#### File updates

#### Protocol deviations

#### File notes

#### Local correspondence

#### on COVID-19/study

### Hints & tips

#### Update your Source

#### data templates to

#### include a COVID-19

#### changes/response

#### Include 'COVID-19'

#### when entering data

#### comments/responses

#### on ALEA, as required

#### Update participant

#### information on ALEA,

#### and/or contact us with

#### any changes

#### Thank you for your

#### ongoing support

#### of the study



**Contact us**  
General trial queries Louise.clement@auckland.ac.nz // 02 7254 3622  
Data management R.cartwright@auckland.ac.nz & L.belaus@auckland.ac.nz